Streetbeat News

Regulatory

BDRX

Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) will present an update on the recruitment and treatment of patients in the ongoing Phase 1 study of MTX-110 in patients with recurrent glioblastoma at the 2023 annual EANO meeting. So far, three patients have been dosed in the first cohort of the study with no observed dose-limiting toxicities. The study aims to assess the feasibility and safety of intermittent infusions of MTX-110 administered via implanted refillable pump and catheter.

Portfolio Pulse from Happy Mohamed

September 21, 2023 | 12:37 pm

SKYX

SKYX Technologies has announced the issuance of 5 additional patents in the U.S. and international markets, adding to the 3 patents announced two weeks ago. The company is pushing for a mandatory safety standardization with the National Electrical Code (NEC) for its ceiling outlet receptacle. The company's code team, led by industry veterans Mark Earley and Eric Jacobson, has submitted significant supporting data regarding hazardous incidents due to electrical wire installations. The company's cash and equivalents totaled $23.7 million as of June 30, 2023. SKYX has also signed an agreement with Material Bank, a leading product material supply company.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:37 pm

SASI

Sigma Additive Solutions, Inc. (NASDAQ:SASI) has announced a 1-for-20 reverse stock split to regain compliance with Nasdaq's minimum bid price per share requirement and facilitate strategic transactions. The company's common stock will begin trading on a split-adjusted basis on September 22, 2023, under the symbol 'SASI'. The reverse stock split will reduce the number of shares from approximately 12,227,135 to around 611,357.

Portfolio Pulse from Happy Mohamed

September 21, 2023 | 12:36 pm

AKTX

Akari Therapeutics (NASDAQ:AKTX) has announced a private placement of its equity securities with existing investors, including Chairman Dr. Ray Prudo and CEO Rachelle Jacques, expected to generate $2 million. The company also received a $2.5 million R&D tax credit from the UK. The private placement will involve the issuance of unregistered American Depository Shares (ADSs) at $3.30 per ADS. The closing is expected on September 22, 2023.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:22 pm

BIOC

Biocept, Inc. (NASDAQ:BIOC) has completed the enrollment of 40 subjects in the feasibility phase of its FORESEE clinical trial, which is evaluating the performance of Biocept's proprietary CNSide assay in monitoring the response to therapy of leptomeningeal metastases (LM). The company aims to establish CNSide as a standard of care under the National Comprehensive Cancer Network guidelines. The trial is designed to measure the impact of CNSide on physicians' clinical decisions. Biocept expects to have results from the feasibility phase of the trial in the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:21 pm

PPBT

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) will present new biomarker data for its Phase 1 study of CM24 in combination with Nivolumab in patients with advanced pancreatic cancer at the AACR Special Conference on September 28, 2023. The data will be shared via a press release after the poster presentation.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:21 pm

BABA

KWEB

MCHI

Alibaba's stock is trading lower, in line with the broader indexes iShares MSCI China ETF and KraneShares Trust KraneShares CSI China Internet ETF. This follows the Federal Reserve's hawkish pause in its tightening cycle, a weakening yuan, and China's housing market crisis. Alibaba recently announced plans to reorganize its businesses into six independently run entities.

Portfolio Pulse from Anusuya Lahiri

September 21, 2023 | 12:19 pm

EWU

The Bank of England has ended its streak of 14 consecutive interest rate hikes due to lower-than-expected inflation, according to CNBC. This could potentially impact the performance of the iShares MSCI United Kingdom ETF (EWU).

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:11 pm

ETNB

89bio, Inc. (NASDAQ:ETNB) has announced that the U.S. FDA has granted Breakthrough Therapy Designation (BTD) to pegozafermin, a treatment for nonalcoholic steatohepatitis (NASH). The designation is supported by positive data from the ENLIVEN Phase 2b trial of pegozafermin. The company plans to discuss the NASH Phase 3 program with regulatory agencies in the fourth quarter of 2023.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:10 pm

CBAY

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) has initiated a Phase 3b/4 study, AFFIRM, to evaluate the effect of seladelpar on clinical outcomes in patients with cirrhosis due to primary biliary cholangitis (PBC). The study is designed to fulfill post-marketing requirements of the accelerated approval pathway for seladelpar. The study will enroll approximately 192 patients and will last for three years.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:08 pm